Key Summary
- A series of pilots will test ways to get innovative medicines to NHS patients faster.
- The pilots have been developed through a joint government and industry taskforce.
- Nine additional medicines have already been approved for NHS patients in England and Wales.
A new series of pilots, developed through a joint taskforce of the Government, NHS, and the pharmaceutical industry, will begin testing new approaches to medicines pricing, access, and adoption as early as this September.
The initiatives aim to get innovative treatments to NHS patients faster, potentially cutting waiting times by months.
The initial phase supports the government’s broader commitment to double innovative medicines spending from 0.3 percent to 0.6 percent of GDP over the next decade, delivering on commitments set out in the UK–US pharmaceutical arrangement.
One of the primary pilots will focus specifically on how innovative treatments that have already met safety, quality, and clinical standards can be fast-tracked to eligible NHS patients, including those requiring new therapies for rare conditions.
This announcement builds on changes made to the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold in April 2026, which have already led to nine additional medicines being approved for NHS patients in England and Wales.
The recent approvals cover a range of serious and life‑threatening conditions, from blood disorders and autoimmune diseases to several cancers, including brain tumours in young children and advanced stomach cancer.
Officials say the combined measures could give thousands of patients speedier access to potentially life‑changing medicines and, once fully implemented, might yield around five extra NICE approvals each year compared with previous arrangements.
NICE has a track record of approving more than 90 percent of all medicines it assesses.
The pharmaceutical sector remains an important part of the UK economy, creating high‑skilled roles across research, manufacturing and commercial activities.
The Association of the British Pharmaceutical Industry (ABPI) chief executive Richard Torbett said, “The measures announced today are the product of intensive and focused effort between industry and government to ensure NHS patients get the medicines they need.
“While there is more work to be done, today’s news represents an important step on the path to achieving our shared goal of making the UK a world-leading environment for patient access and life sciences investment.
“We have already seen industry respond positively to the Government’s commitment earlier this year to increase investment in innovative medicines. I hope that these delivery measures continue to build investor confidence and enable us to make further progress together.”
